GW
IONS icon

GW & Wade’s Ionis Pharmaceuticals IONS Stock Holding History

GW & Wade’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,039
Closed -$290K – 232
2015
Q2 		$290K Buy
5,039
+39
+0.8% +$2.48K 0.06% 190
2015
Q1 		$318K Buy
+5,000
New +$339K 0.06% 184

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

GW & Wade's IONS Position: Q3 2015 in Review

GW & Wade sold out of Ionis Pharmaceuticals (IONS) in Q3 2015, closing a stake of 5,039 shares — an estimated $290K sold.

GW & Wade first reported a position in IONS in Q1 2015 and held it in 2 quarters. The position peaked at $318K in Q1 2015. 314 funds tracked by Wall St. Rank hold IONS as of Q3 2015.

  • GW & Wade reported no remaining Ionis Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • GW & Wade sold 5,039 Ionis Pharmaceuticals shares in Q3 2015, an estimated $290K.
  • GW & Wade first reported a position in Ionis Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • GW & Wade's Ionis Pharmaceuticals position peaked at $318K in Q1 2015.
  • 314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2015.

Based on GW & Wade's 13F filing for Q3 2015, filed 15 Oct 2015.